Update on Pharm2Farm

RNS Number : 5587B

Braveheart Investment Group plc

08 October 2020

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

8 October 2020

Braveheart Investment Group plc

("Braveheart" or the "Group")

Update on P harm2Farm

Braveheart Investment Group (AIM: BRH) has been advised by Pharm 2 Farm Limited ("P2F") of a short delay in the planned testing of its anti-viral face mask material.

The Health and Safety Executive ("HSE") and its Advisory Committee on Dangerous Pathogens, has revised the policy on working with coronavirus (SARS-CoV-2) and has scheduled an inspection at the test facility where P2F is conducting its trials. This has had the consequential effect of delaying the trial while HSE undertake an inspection of the CL-3 laboratory to ensure all the appropriate safeguards are in place. The laboratory is an established UK university laboratory with all the appropriate documentation in place and administered by international virology experts and Braveheart has been advised by P2F that it does not anticipate any problems with the inspections that would delay completion of the P2F trials beyond 30 November 2020.

The P2F team is working urgently with the University to overcome this problem but also to locate an alternative testing laboratory, if one should be required.

P2F has received a conditional order for 1 million face masks per month for a period of one year from 1 January 2021. This order is subject to contract and conditional on the masks successfully completing antiviral and other performance tests and receiving the necessary PPE certifications.  The order is also conditional on the buyer entering into sales contracts to sell a similar volume of masks per month.

In readiness for commercial release, P2F will shortly make a patent application to protect its technology for producing the antiviral material, which it is confident could be applied to air filters, face masks and other PPE.

Elsewhere in its operations, P2F has now completed the initial trial of its proprietary zinc nanotechnology, with positive results, at a citrus farm in the UK. P2F will commence trials in the USA shortly and if success is replicated in the USA trials, it expects to launch this product in early 2021, for farmers to apply during the 2021 growing season. The product is part of the company's nSitu™ range of nano-agritech materials, designed to support commercial farmers around the world - in this case by helping to protect the USA's annual 8 million tons of citrus fruit crops, with an estimated value of such crops of over $3.3 billion.

For further information:
	Braveheart Investment Group plc Tel: [phone] Trevor Brown, Chief Executive Officer Allenby Capital Limited (Nominated Adviser and Joint Broker) Tel: [phone] David Worlidge / James Hornigold Peterhouse Capital Limited (Joint Broker) Tel: [phone] Heena Karani / Lucy Williams

 

END

 

 

UPDKKFBKPBDDFKK